
Michael L. Maitlanda, Xing Jian Louc, Jacqueline Ramireza, Apurva A. Desaia, Dorit S. Berlinc, Howard L. McLeodb, Ralph R. Weichselbauma, Mark J. Rataina, Russ B. Altmanc, and Teri E. Kleinc aDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Maryland Avenue, Chicago, Illinois bUNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, Kerr Hall, Chapel Hill, North Carolina cDepartment of Genetics, Stanford University, Pasteur Drive, Stanford, California, USA
Vascular Endothelial Growth Factor A, Clinical Trials as Topic, Genotype, Antibodies, Monoclonal, Angiogenesis Inhibitors, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Models, Biological, Bevacizumab, Gene Expression Regulation, Neoplastic, Pharmacogenetics, Neoplasms, Humans
Vascular Endothelial Growth Factor A, Clinical Trials as Topic, Genotype, Antibodies, Monoclonal, Angiogenesis Inhibitors, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Models, Biological, Bevacizumab, Gene Expression Regulation, Neoplastic, Pharmacogenetics, Neoplasms, Humans
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 17 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
